Denali Therapeutics (DNLI) Operating Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Operating Expenses data on file, last reported at $137.4 million in Q1 2026.

• Quarterly Operating Expenses fell 5.65% year-over-year to $137.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $547.1 million (up 6.19% YoY) and the FY2025 annual result came in at $555.3 million, up 10.65% from the prior year.
• Operating Expenses held at $137.4 million in Q1 2026 per DNLI's latest filing, from $137.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $156.0 million in Q1 2023 and bottomed at $108.6 million in Q1 2022.
• The 5-year median for Operating Expenses is $129.8 million (2024), against an average of $127.7 million.
• The widest annual swing landed in 2023, when Operating Expenses soared 43.55%; it then fell 15.2% in 2024.
• Tracing DNLI's Operating Expenses over 5 years: stood at $115.6 million in 2022, then rose by 14.65% to $132.6 million in 2023, then dropped by 2.06% to $129.8 million in 2024, then rose by 5.79% to $137.4 million in 2025, then decreased by 0.01% to $137.4 million in 2026.
• Per Business Quant, the three latest DNLI Operating Expenses figures stand at $137.4 million (Q1 2026), $137.4 million (Q4 2025), and $137.4 million (Q3 2025).

Peer Comparison